Skip Nav Destination
Letter|
March 16, 2023
A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients
Hao Zhao,
Hao Zhao
Peking Union Medical College Hospital, Beijing, China
Search for other works by this author on:
Miao-yan Zhang,
Miao-yan Zhang
Peking Union Medical College Hospital, Beijing, China
Search for other works by this author on:
Kai-ni Shen,
Kai-ni Shen
Peking Union Medical College Hospital, Beijing, China
Search for other works by this author on:
Jun Feng,
Jun Feng
Peking Union Medical College Hospital, Beijing, Florida, China
Search for other works by this author on:
Xin-xin Cao,
Xin-xin Cao
Peking Union Medical College Hospital, Beijing, China
Search for other works by this author on:
Ming-hui Duan,
Ming-hui Duan
Peking Union Medical College Hospital, Beijing, China
Search for other works by this author on:
Dao-bin Zhou,
Dao-bin Zhou
Peking Union Medical College Hospital, Chinese Academy Medical Society&Peking Union Medical College, Beijing, China
Search for other works by this author on:
Lu Zhang,
Peking Union Medical College Hospital, Beijing, China
* Corresponding Author; email: pumczhanglu@163.com
Search for other works by this author on:
Jian Li, Prof
Jian Li, Prof
Peking Union Medical College Hospital, Chinese Academy Medical Society&Peking Union Medical College, Beijing, China
Search for other works by this author on:
Blood blood.2023020009.
Article history
Submitted:
February 6, 2023
Revision Received:
March 9, 2023
Accepted:
March 11, 2023
Citation
Hao Zhao, Miao-yan Zhang, Kai-ni Shen, Jun Feng, Xin-xin Cao, Ming-hui Duan, Dao-bin Zhou, Lu Zhang, Jian Li; A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients. Blood 2023; blood.2023020009. doi: https://doi.org/10.1182/blood.2023020009
Download citation file:
Advertisement
Cited By
Email alerts
Advertisement
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal